[EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:COFERON INC
公开号:WO2015106292A1
公开(公告)日:2015-07-16
Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.
Metabolism of N-alkyldiamines and N-alkylnortropinones by transformed root cultures of Nicotiana and Brugmansia
作者:Henry D Boswell、Birgit Dräger、John Eagles、Carol McClintock、Adrian Parr、Andreas Portsteffen、David J Robins、Richard J Robins、Nicholas J Walton、Chi Wong
DOI:10.1016/s0031-9422(99)00292-7
日期:1999.11
tropinone were fed to transformed root cultures of Nicotianarustica and/or a Brugmansia candida × aurea hybrid. These cultures were made by the transformation of the relevant plant species with Agrobacterium rhizogenes . A number of the metabolites, notably those showing a relatively modest alteration in the N -alkyl substituent, were metabolized in vivo to form homologues of the normal alkaloids biosynthesized
摘要 将一系列 N-甲基腐胺和托品酮的类似物喂入转化的 Nicotiana rustica 和/或 Brugmansia candida × aurea 杂种的根培养物。这些培养物是通过用发根农杆菌转化相关植物物种而制成的。许多代谢物,特别是那些在 N-烷基取代基中表现出相对温和改变的代谢物,在体内代谢形成由这些根生物合成的正常生物碱的同系物。这些产品通过 GC/MS 进行鉴定并与一些合成参考材料进行比较。N-烷基取代基大小发生重大变化的类似物根本没有代谢。在 N. rustica 培养物中,以 1 mM 喂食的类似物显着影响了正常生物碱的分布,在存在 N-n-丙基腐胺的情况下,发现尼古丁最多减少 4 倍。吡咯烷系列和哌啶系列的生物碱之间的比例也受到影响。相比之下,念珠菌×金黄色混合培养物中 1 mM 类似物的存在不会抑制或显着干扰正常生物碱谱的积累。讨论了使用这些培养物从简单的前体制造复杂的新产品的潜力。
Continuous Chemoselective Methylation of Functionalized Amines and Diols with Supercritical Methanol over Solid Acid and Acid−Base Bifunctional Catalysts
bifunctional catalysts (Cs-P-Si mixed oxide and gamma-alumina) was investigated in a continuous-flow, fixed-bed reactor. The use of scCH(3)OH in the reaction of 2-aminoethanol with methanol (amine/CH(3)OH = 1/10.8) over the solid catalysts led to a significant improvement in the chemoselectivity of the N-methylation. Among the catalysts examined, the Cs-P-Si mixed oxide provided the most efficient catalyst
[EN] BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION<br/>[FR] LIGANDS DE BROMODOMAINE POUVANT SE DIMÉRISER DANS UNE SOLUTION AQUEUSE
申请人:COFERON INC
公开号:WO2015081280A1
公开(公告)日:2015-06-04
Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
[EN] BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME<br/>[FR] LIGANDS BROMODOMAINES BIVALENTS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:COFERON INC
公开号:WO2015081284A1
公开(公告)日:2015-06-04
Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on different proteins. For example, in one aspect, a bivalent compound or a pharmaceutically acceptable salt, stereoisomer, metabolite, or hydrate thereof is provided. In another aspect, a method of treating a disease associated with a protein having tandem bromodomains in a patient in need thereof is provided. The method comprises administering to the patient the bivalent compound as described.